Haematological anticancer drugs in Europe: any added value at the time of approval?-Reference-Cited by-同舟云学术

Haematological anticancer drugs in Europe: any added value at the time of approval?

Published:2007-05-25 Issue:7 Volume:63 Page:713-719
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Bertele’ Vittorio,Banzi Rita,Capasso Filippo,Tafuri Giovanni,Trotta Francesco,Apolone Giovanni,Garattini Silvio

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-007-0296-2.pdf

Reference19 articles.

1. Garattini S, Bertele’ V (2002) Efficacy, safety, and cost of new anticancer drugs. Br Med J 325(7358):269–271

2. Apolone G, Joppi R, Bertele’ V, Garattini S (2005) Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer 93:504–509

3. Netzer T (2006) European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency. Eur J Cancer 42:446–455

4. CPMP/EWP/205/95/Rev. 3 (2005) Guideline on the evaluation of anticancer medicinal products in man. http://www.emea.europa.eu/pdfs/human/ewp/020595en.pdf . Cited 7 Sept 2006

5. National Institute for Clinical Excellence (2002) Guidance on the use of rituximab for recurrent or refractory Stage III or IV follicular non-Hodgkin’s lymphoma. National Institute for Clinical Excellence, National Health Service, UK

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis;Pharmacology Research & Perspectives;2021-07-07

2. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy;BMJ Open;2019-12

3. From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs;Seminars in Cancer Biology;2017-08

4. Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?;ESMO Open;2016

5. Approvals of drugs with uncertain benefit–risk profiles in Europe;European Journal of Internal Medicine;2015-10